Tradestie Institutional Equity Comparison Engine · Market Close Mar 31, 2026

ITRM vs CLSD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ITRM Captures Overall Composite Edge (50.5 HOLD vs 43.3 HOLD), While CLSD Leads 2–1 on Growth & Valuation Pillars

ITRM Overall Winner 6-Pillar Tally: ITRM 1 – 2 CLSD (3 Tie) Matrix Metrics: ITRM 3 – 2 CLSD

As of Mar 31, 2026, Iterum Therapeutics plc Ordinary Share (ITRM) captures the overall head-to-head institutional edge over Clearside Biomedical, Inc. (CLSD) on higher Unified Composite conviction (50.5/100 HOLD vs. 43.3/100 HOLD) after splitting the core matrix 3–2 (led by Profitability & Quality), while CLSD wins 2–1 across the 6-pillar growth and valuation breakdown. ITRM trades at $0.03 (N/M Forward P/E, -1982.3% operating margin) versus CLSD at $0.41 (N/M Forward P/E, -3502.5% operating margin).

  • Growth vs. Quality Trade-Off: ITRM earns the overall head-to-head edge with a stronger Unified Composite Score (50.5/100 HOLD vs. CLSD 43.3/100 HOLD) and 1.61β · 508% Vol risk profile, whereas CLSD leads top-line expansion (-80.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ITRM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile CLSD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 17.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ITRM vs CLSD
ITRM NASDAQ Head-to-Head Winner
Iterum Therapeutics plc Ordinary Share
Pharmaceutical Preparations
$0.03
-57.39% 1D
Market Cap $3.8M
TTM Revenue $390,000
Forward P/E N/M
Beta / 30D Vol 1.61β · 508% Vol
Unified Composite Score
50.5 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 75.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.9%), weak momentum, RSI 26
RSI-14: 25.9 · SMA20: $0.15 · SMA50: $0.23
CLSD NASDAQ
Clearside Biomedical, Inc. Common Stock
Pharmaceutical Preparations
$0.41
-26.96% 1D
Market Cap $2.9M
TTM Revenue $3.3M
Forward P/E N/M
Beta / 30D Vol 2.24β · 269% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 40.0 Fund 43.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 17
RSI-14: 17.4 · SMA20: $2.98 · SMA50: $3.60

6-Pillar Scorecard Institutional Category Breakdown (ITRM 1 – 2 CLSD)

Columns: Metric · ITRM · CLSD
1. Valuation Multiples CLSD
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 9.6x 0.9x
2. Growth & Scale CLSD
Revenue Growth (YoY) -100.0% -80.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $390,000 $3.3M
Market Cap $3.8M $2.9M
3. Profitability & Quality ITRM
Gross Margin 29.7% 88.1%
Operating Margin -1982.3% -3502.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -555.7% -1310.0%
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) -$19M EBITDA -$23M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage -555.7% ROE -1310.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Pharmaceutical Preparations Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ITRM (3) vs CLSD (2)
Institutional Metric ITRM CLSD Criterion Row Edge
Market Capitalization
Scale
$3.8M $2.9M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% -80.6% Higher Growth CLSD
Operating Margin (TTM)
Profitability
-1982.3% -3502.5% Higher Margin ITRM
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-555.7% -1310.0% Higher ROE ITRM
52-Week Range Position
Momentum
0% ($0–$1) 1% ($0–$17) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.61β · 508% Vol 2.24β · 269% Vol Lower Realized Risk CLSD
Unified Institutional Score
Composite Signal
50.5 / 100 (HOLD) 43.3 / 100 (HOLD) Higher Composite ITRM
Trailing 12M Revenue (USD)
Operating Scale
$390,000 $3.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
29.7% 88.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.6x EV/Rev N/M PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$19M EBITDA (-555.7% ROE) -$23M EBITDA (-1310.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ITRM +59.41 pp
ITRM: -29.45% · CLSD: -88.86%
3M Horizon CLSD +43.61 pp
ITRM: -32.05% · CLSD: +11.56%
6M Horizon CLSD +7.88 pp
ITRM: -54.0% · CLSD: -46.12%
1Y Horizon ITRM +33.63 pp
ITRM: -63.49% · CLSD: -97.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ITRM vs CLSD. Trailing 12-month operating profitability (ITRM -1982.3% vs CLSD -3502.5%) and valuation multiples (ITRM N/M vs CLSD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ITRM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$390,000
Gross Margin29.7%
Op. Margin-1982.3%
ROE / Fwd P/E-555.7% · N/M
CLSD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.3M
Gross Margin88.1%
Op. Margin-3502.5%
ROE / Fwd P/E-1310.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ITRM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ITRM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CLSD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLSD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ITRM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8M market capitalization and -1982.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CLSD Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $2.9M market capitalization and -3502.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ITRM vs CLSD Key Questions & Quantitative Answers

As of Mar 31, 2026, Iterum Therapeutics plc Ordinary Share (ITRM) captures the overall head-to-head institutional edge over Clearside Biomedical, Inc. (CLSD) on higher Unified Composite conviction (50.5/100 HOLD vs. 43.3/100 HOLD) after splitting the core matrix 3–2 (led by Profitability & Quality), while CLSD wins 2–1 across the 6-pillar growth and valuation breakdown. ITRM trades at $0.03 (N/M Forward P/E, -1982.3% operating margin) versus CLSD at $0.41 (N/M Forward P/E, -3502.5% operating margin). Growth vs. Quality Trade-Off: ITRM earns the overall head-to-head edge with a stronger Unified Composite Score (50.5/100 HOLD vs. CLSD 43.3/100 HOLD) and 1.61β · 508% Vol risk profile, whereas CLSD leads top-line expansion (-80.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ITRM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile CLSD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 17.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CLSD leads the Growth & Scale pillar: ITRM posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $390,000 TTM revenue (29.7% gross margin, -1982.3% operating margin), compared with CLSD at -80.6% YoY revenue growth and +0.0% YoY earnings growth on $3.3M TTM revenue (88.1% gross margin, -3502.5% operating margin). On trailing 12-month operating scale, ITRM generates $390,000 in USD-normalized revenue versus $3.3M for CLSD. In operating R&D and SG&A reinvestment, ITRM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLSD.

CLSD screens cheaper on headline valuation multiples. ITRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas CLSD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ITRM (-555.7% ROE) versus CLSD (-1310.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ITRM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.61β · 508% Vol realized risk). By comparison, CLSD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.24β · 269% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Mar 31, 2026. For educational research only; not investment advice.